https://www.selleckchem.com/pr....oducts/atuzabrutinib
001) and faecal calprotectin from 776 to 305 μg/g (P 0.001). Ustekinumab treatment in patients with highly refractory Crohn's disease resulted in high long-term treatment persistence and significantly reduced disease activity, assessed with objective markers for intestinal inflammatory activity. Ustekinumab treatment in patients with highly refractory Crohn's disease resulted in high long-term treatment persistence and significantly reduced disease activity, assessed with objective markers for intestinal inflammatory activity
Like
Comment
Share
